A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic
profile of HB002.1T in combination with different chemotherapy regimens administered to
patients with advanced solid tumors.